10 assets in Chondrosarcoma

Therapeutic assets addressing Chondrosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ivosidenib Chondrosarcoma	Memorial Sloan Kettering Cancer Center	P2	B (60)
Cis-Diamminedichloroplatinum Ii Chondrosarcoma	Eli Lilly and Company	P1/2	CCC (55)
Adapt-001 Chondrosarcoma	EpicentRx, Inc.	P2	CCC (53)
Atezolizumab Chondrosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Capivasertib Chondrosarcoma	M.D. Anderson Cancer Center	P1	CC (43)
Durvalumab Chondrosarcoma	Eli Lilly and Company	P1	CC (43)
Ipn 60090 Chondrosarcoma	M.D. Anderson Cancer Center	P1	CC (43)
LY 3410738 Chondrosarcoma	Eli Lilly and Company	P1	CC (43)
89zr-dfo-n-suc-c9scfv Chondrosarcoma	Var2 Pharmaceuticals	Early P1	C (39)
89Zr-DFO-N-Suc-F8scFv Chondrosarcoma	Var2 Pharmaceuticals	Early P1	C (39)